• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?

作者信息

Sharma Surendra K, Dheda Keertan

机构信息

Department of Molecular Medicine, Jamia Hamdard Institute of Molecular Medicine, Jamia Hamdard (Deemed-to-be-University), New Delhi; Departments of General Medicine & Respiratory Medicine, Jawaharlal Nehru Medical College (JNMC), Datta Meghe Institute of Medical Science, Wardha, India.

Department of Medicine & UCT Lung Institute, Division of Pulmonology, Centre for Lung Infection & Immunity, University of Cape Town, Cape Town, South Africa; Department of Immunology & Infection, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.

出版信息

Indian J Med Res. 2019 Mar;149(3):309-312. doi: 10.4103/ijmr.IJMR_579_19.

DOI:10.4103/ijmr.IJMR_579_19
PMID:31249191
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6607808/
Abstract
摘要

相似文献

1
What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?世界卫生组织耐药结核病治疗综合指南中有哪些新内容？
Indian J Med Res. 2019 Mar;149(3):309-312. doi: 10.4103/ijmr.IJMR_579_19.
2
Drug-resistant tuberculosis: reality and potential threat.耐药结核病：现状与潜在威胁
Int J Tuberc Lung Dis. 2010 Mar;14(3):255-8.
3
Phenotypic and genotypic analysis of multidrug-resistant tuberculosis in Ethiopia.埃塞俄比亚耐多药结核病的表型和基因型分析。
Int J Tuberc Lung Dis. 2010 Oct;14(10):1259-65.
4
Multidrug-resistant/extensively drug-resistant tuberculosis in Greece: predominance of Mycobacterium tuberculosis genotypes endemic in the Former Soviet Union countries.希腊的耐多药/广泛耐药结核病：前苏联国家流行的结核分枝杆菌基因型占主导地位。
Clin Microbiol Infect. 2017 Dec;23(12):1002-1004. doi: 10.1016/j.cmi.2017.07.002. Epub 2017 Jul 8.
5
Resistance to anti-tuberculosis medications in the Horn of Africa.非洲之角的抗结核药物耐药性。
Int J Tuberc Lung Dis. 2011 Mar;15(3):414-6.
6
Practical considerations to implement the shorter regimen to MDR-TB patients in China.在中国对耐多药结核病患者实施较短疗程的实际考量。
Clin Microbiol Infect. 2018 Oct;24(10):1035-1036. doi: 10.1016/j.cmi.2018.04.026. Epub 2018 May 3.
7
Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa.南非广泛耐药结核病的耐药性不断增加。
Emerg Infect Dis. 2011 Mar;17(3):510-3. doi: 10.3201/eid1703.101363.
8
Management of multidrug resistant tuberculosis.耐多药结核病的管理。
Semin Respir Crit Care Med. 2013 Feb;34(1):44-59. doi: 10.1055/s-0032-1333546. Epub 2013 Mar 4.
9
State of the Art series on drug-resistant tuberculosis: it's time to protect fluoroquinolones.耐药结核病的最新进展系列：是时候保护氟喹诺酮类药物了。
Int J Tuberc Lung Dis. 2009 Nov;13(11):1319.
10
Challenges and Outlooks in Multi-drug Resistant Tuberculosis.耐多药结核病的挑战与展望
Arch Bronconeumol. 2017 Aug;53(8):417-418. doi: 10.1016/j.arbres.2017.01.018. Epub 2017 Mar 14.

引用本文的文献

1
Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.对抗耐药结核病的进展：全面综述、新策略及专利态势
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar;398(3):2127-2150. doi: 10.1007/s00210-024-03466-0. Epub 2024 Oct 8.
2
Audit of essential medicine listing and registration status of medicines on standard treatment guidelines in Kenya, Tanzania and Uganda: Case study of malaria, tuberculosis, hypertension and type 2 diabetes mellitus.肯尼亚、坦桑尼亚和乌干达关于基本药物清单及标准治疗指南中药物注册状况的审核：疟疾、结核病、高血压和2型糖尿病案例研究
JRSM Open. 2024 Mar 29;15(3):20542704241232814. doi: 10.1177/20542704241232814. eCollection 2024 Mar.
3
mHealth application for improving treatment outcomes for patients with multidrug-resistant tuberculosis in Vietnam: an economic evaluation protocol for the V-SMART trial.越南利用移动医疗应用改善耐多药结核病患者治疗结局：V-SMART 试验的经济评价方案。
BMJ Open. 2023 Dec 11;13(12):e076778. doi: 10.1136/bmjopen-2023-076778.
4
Computational Insight into Substrate-Induced Conformational Changes in Methionyl-tRNA Synthetase of Mycobacterium Tuberculosis.计算洞察结核分枝杆菌甲硫氨酰-tRNA 合成酶的底物诱导构象变化。
Protein J. 2023 Oct;42(5):533-546. doi: 10.1007/s10930-023-10135-3. Epub 2023 Jul 4.
5
Oral regimen for multi-drug-resistant TB can promote patient-centred and community-based treatment.耐多药结核病的口服治疗方案可促进以患者为中心和基于社区的治疗。
J Family Med Prim Care. 2021 Dec;10(12):4607-4608. doi: 10.4103/jfmpc.jfmpc_2502_20. Epub 2021 Dec 27.
6
Does optimized adherence support improve treatment outcomes in RR / MDR-TB patients on 18-20 months regimen in Tbilisi, Georgia?在格鲁吉亚第比利斯，接受 18-20 个月方案治疗的 RR/MDR-TB 患者中，优化的依从性支持是否能改善治疗结局？
J Infect Dev Ctries. 2021 Sep 29;15(9.1):34S-42S. doi: 10.3855/jidc.13783.
7
Development of a nomogram for predicting treatment default under facility-based directly observed therapy short-course in a region with a high tuberculosis burden.在结核病负担较高地区，基于设施的直接观察短程治疗中预测治疗缺失的列线图的开发。
Ther Adv Infect Dis. 2021 Jul 29;8:20499361211034066. doi: 10.1177/20499361211034066. eCollection 2021 Jan-Dec.
8
Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.呈现处于不同药物研发阶段的新型抗结核药物的化学类别：2010 - 2020年综述
Pharmaceuticals (Basel). 2021 May 13;14(5):461. doi: 10.3390/ph14050461.
9
Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications.控制印度的耐药结核病疫情：挑战与影响。
Epidemiol Health. 2021;43:e2021022. doi: 10.4178/epih.e2021022. Epub 2021 Apr 7.
10
Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults.成人肺结核治疗结局预测模型的系统评价。
BMJ Open. 2021 Mar 2;11(3):e044687. doi: 10.1136/bmjopen-2020-044687.

本文引用的文献

1
Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen.氟喹诺酮类耐药结核病患者在接受贝达喹啉为基础的治疗方案时，中断利奈唑胺。
Int J Infect Dis. 2019 Aug;85:74-79. doi: 10.1016/j.ijid.2019.04.028. Epub 2019 May 14.
2
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.一项针对耐利福平结核病的较短疗程的试验。
N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13.
3
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.德拉马尼联合优化背景治疗方案治疗耐多药结核病的疗效和安全性：一项多中心、随机、双盲、安慰剂对照、平行分组 3 期临床试验。
Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7.
4
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.肺耐多药结核病成功治疗结果的相关因素：一项个体患者数据荟萃分析。
Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.
5
Drug-resistant tuberculosis: is India ready for the challenge?耐多药结核病：印度是否准备好应对这一挑战？
BMJ Glob Health. 2018 Aug 10;3(4):e000971. doi: 10.1136/bmjgh-2018-000971. eCollection 2018.
6
Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.贝达喹啉与含注射剂的耐多药结核病治疗方案：成本效益分析。
Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):677-689. doi: 10.1080/14737167.2018.1507821. Epub 2018 Aug 23.
7
The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?已知之恶：使用注射剂治疗耐多药结核病是否合理？
Int J Tuberc Lung Dis. 2017 Nov 1;21(11):1114-1126. doi: 10.5588/ijtld.17.0468.
8
Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.标准化短程方案治疗耐多药结核病的疗效和安全性：个体患者数据和汇总数据荟萃分析。
Eur Respir J. 2017 Jul 27;50(1). doi: 10.1183/13993003.00061-2017. Print 2017 Jul.
9
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.耐多药、广泛耐药和不可治愈结核病的流行病学、发病机制、传播、诊断及管理
Lancet Respir Med. 2017 Mar 15. doi: 10.1016/S2213-2600(17)30079-6.
10
Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study.南非广泛耐药结核病患者的长期结局：一项队列研究。
Lancet. 2014 Apr 5;383(9924):1230-9. doi: 10.1016/S0140-6736(13)62675-6. Epub 2014 Jan 17.